[Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies]
| Autor: | G, Créhange, J-F, Bosset, P, Maingon |
|---|---|
| Přispěvatelé: | Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) |
| Jazyk: | francouzština |
| Rok vydání: | 2011 |
| Předmět: |
MESH: Radiation-Sensitizing Agents
Radiation-Sensitizing Agents MESH: Combined Modality Therapy Time Factors Organoplatinum Compounds MESH : Radiation-Sensitizing Agents MESH : Antineoplastic Combined Chemotherapy Protocols Leucovorin Cetuximab MESH : Camptothecin MESH : Leucovorin MESH : Randomized Controlled Trials as Topic Deoxycytidine MESH : Multicenter Studies as Topic MESH : Radiotherapy Conformal [ SDV.CAN ] Life Sciences [q-bio]/Cancer MESH: Antibodies Monoclonal MESH : Clinical Trials Phase II as Topic MESH : Adenocarcinoma MESH: Clinical Trials Phase III as Topic Antineoplastic Combined Chemotherapy Protocols Multicenter Studies as Topic MESH : Rectal Neoplasms Randomized Controlled Trials as Topic MESH: Treatment Outcome MESH: Antimetabolites Antineoplastic MESH : Antimetabolites Antineoplastic MESH: Organoplatinum Compounds Antibodies Monoclonal MESH : Chemotherapy Adjuvant Combined Modality Therapy Neoadjuvant Therapy Oxaliplatin MESH: Antineoplastic Combined Chemotherapy Protocols Treatment Outcome Chemotherapy Adjuvant MESH: Chemotherapy Adjuvant MESH : Antibodies Monoclonal MESH: Radiotherapy Conformal MESH : Fluorouracil MESH: Camptothecin Fluorouracil MESH: Clinical Trials Phase II as Topic MESH : Time Factors MESH: Forecasting Antimetabolites Antineoplastic MESH: Neoadjuvant Therapy [SDV.CAN]Life Sciences [q-bio]/Cancer MESH : Treatment Outcome Adenocarcinoma Antibodies Monoclonal Humanized Irinotecan MESH : Organoplatinum Compounds Clinical Trials Phase II as Topic MESH : Deoxycytidine Humans MESH : Forecasting MESH : Clinical Trials Phase III as Topic Capecitabine MESH: Humans Rectal Neoplasms MESH : Humans MESH: Adenocarcinoma MESH: Time Factors MESH: Deoxycytidine MESH: Rectal Neoplasms MESH: Randomized Controlled Trials as Topic Clinical Trials Phase III as Topic MESH: Multicenter Studies as Topic Camptothecin Radiotherapy Conformal MESH : Combined Modality Therapy MESH: Leucovorin MESH : Neoadjuvant Therapy MESH: Fluorouracil Forecasting |
| Zdroj: | Cancer Radiothérapie Cancer Radiothérapie, Elsevier Masson, 2011, 15 (6-7), pp.440-444. ⟨10.1016/j.canrad.2011.05.006⟩ Cancer Radiothérapie, Elsevier Masson, 2011, 15 (6-7), pp.440-444. 〈10.1016/j.canrad.2011.05.006〉 |
| ISSN: | 1278-3218 |
| DOI: | 10.1016/j.canrad.2011.05.006⟩ |
| Popis: | International audience; Protracted preoperative radiochemotherapy with a 5-FU-based scheme, or a short course of preoperative radiotherapy without chemotherapy, are the standard neoadjuvant treatments for resectable stage II-III rectal cancer. Local failure rates are low and reproducible, between 6 and 15% when followed with a "Total Mesorectal Excision". Nevertheless, the therapeutic strategy needs to be improved: distant metastatic recurrence rates remain stable around 30 to 35%, while both sphincter and sexual sequels are still significant. The aim of the present paper was to analyse the ongoing trials listed on the following search engines: the Institut National du Cancer in France, the National Cancer Institute and the National Institute of Health in the United States, and the major cooperative groups. Keywords for the search were: "rectal cancer", "preoperative radiotherapy", "phase II-III", "preoperative chemotherapy", "adjuvant chemotherapy" and "surgery". Twenty-three trials were selected and classified in different groups, each of them addressing a question of strategy: (1) place of adjuvant chemotherapy; (2) optimization of preoperative radiotherapy; (3) evaluation of new radiosensitization protocols and/or neoadjuvant chemotherapy; (4) optimization of techniques and timing of surgery; (5) place of radiotherapy for non resectable or metastatic tumors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect